Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Turkey (Türkiye) with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Phase: Not applicable Country / region: Turkey (Türkiye) Clear all

119 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20091
20151
20161
20176
20185
201910
20207
20218
202217
202316
202424
202512
202611

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed71
Recruiting19
Unknown status19
Not yet recruiting5
Active, not recruiting4
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Saglik Bilimleri Universitesi7
Hacettepe University6
Akdeniz University3
Bezmialem Vakif University3
Dokuz Eylul University3
Istanbul Medipol University Hospital3
Istinye University3
Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital3
Kirsehir Ahi Evran Universitesi3
Marmara University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive119
Dyspnea24
Anxiety Disorders11
Fatigue8
Sleep Initiation and Maintenance Disorders7
Asthma4
Pain4
Bronchitis, Chronic2
Cough2
Kinesiophobia2

Trials

Showing 1 to 25 of 119. Each trial links to its page on Pharma Observatory.

19 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.